Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Supported Approved Vesicles Expressed in all Tissue enhanced duodenum: 183.8;small intestine: 297.5 testis: 83.7 ACE2 ENSG00000130234 Angiotensin I converting enzyme 2 X 15561033-15602148 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000288, CAB026174 Supported Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable) Tissue enhanced Group enriched 6 duodenum: 186.1;gallbladder: 100.6;kidney: 93.3;small intestine: 266.6;testis: 92.6 heart muscle: 23.1 ACY1 ENSG00000243989 Aminoacylase 1 3 51983340-51989197 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003695, HPA036174, HPA036175 Supported Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable) Expressed in all Group enriched 6 duodenum: 182.6;kidney: 462.6;liver: 146.9;small intestine: 158.4 thyroid gland: 40.0 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM11 MDC ENSG00000073670 ADAM metallopeptidase domain 11 17 44759031-44781846 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cerebral cortex: 19.8 heart muscle: 4.5 ADAM12 MCMPMltna, MLTN ENSG00000148848 ADAM metallopeptidase domain 12 10 126012381-126388455 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030866, HPA030867, HPA030868 Supported Supported Plasma membrane Renal cancer:2.39e-14 (unfavourable) Mixed Tissue enriched 8 placenta: 236.1 cervix, uterine: 29.5 ADAM15 MDC15 ENSG00000143537 ADAM metallopeptidase domain 15 1 155050566-155062775 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011633, HPA072878 Uncertain Uncertain Vesicles Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable) Expressed in all Expressed in all skin: 72.8 ADAM17 CD156B, cSVP, TACE ENSG00000151694 ADAM metallopeptidase domain 17 2 9488486-9555792 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010738, CAB025906, HPA051575 Approved Supported Cytosol Urothelial cancer:4.23e-5 (unfavourable) Expressed in all Expressed in all placenta: 33.9 ADAM18 ADAM27, tMDCIII ENSG00000168619 ADAM metallopeptidase domain 18 8 39584489-39730064 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 84 testis: 8.3 all non-specific tissues: 0.0 ADAM19 MLTNB ENSG00000135074 ADAM metallopeptidase domain 19 5 157395534-157575775 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA055537 Approved Vesicles Renal cancer:3.90e-12 (unfavourable) Expressed in all Mixed lymph node: 34.9 ADAM2 CT15, FTNB, PH-30b, PH30 ENSG00000104755 ADAM metallopeptidase domain 2 8 39743735-39838289 Enzymes, Predicted membrane proteins Evidence at protein level CAB022390, HPA024621, HPA026581 Supported Tissue enhanced Tissue enriched 288 testis: 41.7 breast: 0.1 ADAM20 ENSG00000134007 ADAM metallopeptidase domain 20 14 70522358-70535015 Enzymes, Predicted membrane proteins Evidence at protein level HPA059377 Supported Not detected Tissue enriched 76 testis: 9.2 cerebral cortex,endometrium,skin: 0.1 ADAM21 ADAM31 ENSG00000139985 ADAM metallopeptidase domain 21 14 70452157-70459899 Enzymes, Predicted membrane proteins Evidence at protein level HPA059016 Uncertain Not detected Tissue enriched 31 testis: 15.4 cerebral cortex: 0.5 ADAM22 MDC2 ENSG00000008277 ADAM metallopeptidase domain 22 7 87934143-88202889 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050325 Approved Cell Junctions Mixed Tissue enhanced cerebral cortex: 47.7 prostate: 17.5 ADAM23 MDC3 ENSG00000114948 ADAM metallopeptidase domain 23 2 206443539-206621130 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012130, CAB033276 Uncertain Mixed Group enriched 6 cerebral cortex: 55.7;parathyroid gland: 132.9 heart muscle: 16.4 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 ADAM29 CT73, svph1 ENSG00000168594 ADAM metallopeptidase domain 29 4 174829668-174978180 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 80 testis: 72.8 endometrium: 0.9 ADAM30 svph4 ENSG00000134249 ADAM metallopeptidase domain 30 1 119893533-119896495 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA026080 Uncertain Not detected Tissue enriched 468 testis: 46.8 all non-specific tissues: 0.0 ADAM32 ENSG00000197140 ADAM metallopeptidase domain 32 8 39106990-39284911 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044156, HPA062151 Approved Approved Nucleus
Vesicles Not detected Tissue enriched 31 testis: 28.7 epididymis: 0.9 ADAM33 C20orf153, dJ964F7.1, DKFZp434K0521 ENSG00000149451 ADAM metallopeptidase domain 33 20 3667965-3682246 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA067152, HPA071758 Approved Uncertain Nuclear speckles
Plasma membrane Mixed Mixed endometrium: 102.9 ADAM7 EAPI, GP-83 ENSG00000069206 ADAM metallopeptidase domain 7 8 24440930-24526970 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008879 Supported Group enriched Tissue enriched 198 epididymis: 4461.2 seminal vesicle: 22.5 ADAM8 CD156, CD156a, MS2 ENSG00000151651 ADAM metallopeptidase domain 8 10 133262403-133276868 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064637 Approved Renal cancer:3.99e-10 (unfavourable) Expressed in all Tissue enhanced bone marrow: 43.9;spleen: 33.5 appendix: 30.9 ADAM9 CORD9, KIAA0021, MCMP, MDC9, Mltng ENSG00000168615 ADAM metallopeptidase domain 9 8 38996869-39105144 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004000 Approved Endoplasmic reticulum
Vesicles Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 116.7 ADAMDEC1 M12.219 ENSG00000134028 ADAM-like, decysin 1 8 24384285-24406013 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Expressed in all Tissue enhanced colon: 214.7;rectum: 344.3;small intestine: 485.5 duodenum: 194.4 ADAMTS1 C3-C5, KIAA1346, METH1 ENSG00000154734 ADAM metallopeptidase with thrombospondin type 1 motif, 1 21 26835747-26845409 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016394, HPA031498, HPA031499 Uncertain Validated Cytosol Head and neck cancer:5.13e-4 (unfavourable) Expressed in all Tissue enhanced ovary: 410.9 adipose tissue: 276.6 ADAMTS10 ADAM-TS10 ENSG00000142303 ADAM metallopeptidase with thrombospondin type 1 motif, 10 19 8580242-8610735 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040223 Uncertain Approved Cytosol Renal cancer:4.55e-9 (unfavourable) Expressed in all Mixed endometrium: 5.9 ADAMTS12 ENSG00000151388 ADAM metallopeptidase with thrombospondin type 1 motif, 12 5 33523535-33892192 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA035973 Uncertain Urothelial cancer:6.78e-4 (unfavourable) Mixed Mixed adipose tissue: 9.7 ADAMTS13 C9orf8, DKFZp434C2322, FLJ42993, MGC118899, MGC118900, TTP, vWF-CP, VWFCP ENSG00000160323 ADAM metallopeptidase with thrombospondin type 1 motif, 13 9 133414358-133459402 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042014, HPA042844 Uncertain Mixed Mixed liver: 6.2 ADAMTS14 ENSG00000138316 ADAM metallopeptidase with thrombospondin type 1 motif, 14 10 70672803-70762441 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA034605 Uncertain Cytosol Mixed Tissue enhanced gallbladder: 10.9;placenta: 11.0 urinary bladder: 4.5 ADAMTS15 ENSG00000166106 ADAM metallopeptidase with thrombospondin type 1 motif, 15 11 130448974-130476641 Enzymes, Predicted secreted proteins Evidence at transcript level HPA042867 Uncertain Approved Cytosol Urothelial cancer:5.63e-5 (unfavourable), Glioma:9.00e-4 (favourable), Lung cancer:9.72e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 30.2;placenta: 23.5 breast: 11.0 ADAMTS16 ADAMTS16s ENSG00000145536 ADAM metallopeptidase with thrombospondin type 1 motif, 16 5 5140330-5320304 Enzymes, Predicted secreted proteins Evidence at protein level Renal cancer:3.29e-5 (favourable) Mixed Tissue enhanced gallbladder: 10.0;ovary: 11.4 adipose tissue: 6.3 ADAMTS17 FLJ16363, FLJ32769 ENSG00000140470 ADAM metallopeptidase with thrombospondin type 1 motif, 17 15 99971589-100342005 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA062487 Approved Nucleus Mixed Mixed endometrium: 3.5 ADAMTS18 ADAMTS21 ENSG00000140873 ADAM metallopeptidase with thrombospondin type 1 motif, 18 16 77247813-77435114 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044326 Uncertain Mixed Tissue enriched 16 placenta: 28.9 cervix, uterine: 1.8 ADAMTS19 ENSG00000145808 ADAM metallopeptidase with thrombospondin type 1 motif, 19 5 129460265-129738683 Enzymes, Predicted secreted proteins Evidence at transcript level HPA056171, HPA058438 Uncertain Approved Vesicles
Midbody Tissue enhanced Group enriched 13 cervix, uterine: 16.4;endometrium: 16.4;placenta: 5.2;smooth muscle: 8.9 adrenal gland: 0.9 ADAMTS2 ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif, 2 5 179110851-179345430 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA028444 Uncertain Approved Vesicles
Plasma membrane Renal cancer:1.71e-8 (unfavourable) Expressed in all Mixed placenta: 27.2 ADAMTS20 GON-1 ENSG00000173157 ADAM metallopeptidase with thrombospondin type 1 motif, 20 12 43353866-43551921 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027608, HPA027609 Uncertain Not detected Not detected placenta: 0.8 ADAMTS3 ADAMTS-4, KIAA0366 ENSG00000156140 ADAM metallopeptidase with thrombospondin type 1 motif, 3 4 72280969-72568799 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA021368, HPA021369 Uncertain Approved Intermediate filaments Mixed Tissue enhanced parathyroid gland: 7.9 testis: 3.7 ADAMTS4 ADAMTS-2, ADMP-1, KIAA0688 ENSG00000158859 ADAM metallopeptidase with thrombospondin type 1 motif, 4 1 161184308-161199056 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB025876, HPA051296, HPA068374 Uncertain Approved Nuclear speckles Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 62.7 appendix: 23.4 ADAMTS5 ADAMTS11, ADMP-2 ENSG00000154736 ADAM metallopeptidase with thrombospondin type 1 motif, 5 21 26917912-26966513 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA005661, CAB025996, HPA030906, HPA030908 Approved Supported Nucleoplasm Renal cancer:2.46e-4 (unfavourable), Thyroid cancer:8.54e-4 (unfavourable) Mixed Tissue enhanced placenta: 42.0 ovary: 24.2 ADAMTS6 ADAM-TS6 ENSG00000049192 ADAM metallopeptidase with thrombospondin type 1 motif, 6 5 65148736-65481920 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA043441 Supported Mixed Tissue enhanced placenta: 2.7 gallbladder: 2.3 ADAMTS7 ADAM-TS7, DKFZp434H204 ENSG00000136378 ADAM metallopeptidase with thrombospondin type 1 motif, 7 15 78759203-78811431 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA045284, HPA048453 Uncertain Approved Vesicles Stomach cancer:9.53e-4 (unfavourable) Mixed Tissue enhanced endometrium: 7.2 heart muscle: 4.7 ADAMTS8 ADAM-TS8, FLJ41712, METH2 ENSG00000134917 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11 130404925-130428993 Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at transcript level HPA066349 Approved Endometrial cancer:1.38e-4 (favourable) Tissue enhanced Tissue enhanced appendix: 11.2;lung: 15.6 seminal vesicle: 5.5 ADAMTS9 KIAA1312 ENSG00000163638 ADAM metallopeptidase with thrombospondin type 1 motif, 9 3 64515654-64688000 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028567, HPA028577, HPA028601 Approved Supported Endoplasmic reticulum
Vesicles Expressed in all Tissue enhanced placenta: 45.0 adipose tissue: 31.9 AEBP1 ACLP ENSG00000106624 AE binding protein 1 7 44104361-44114562 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB009966, HPA047724, HPA063595, HPA064970 Supported Supported Nucleoplasm
Vesicles
Cytosol Renal cancer:9.31e-9 (unfavourable), Glioma:1.10e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 297.8 AFG3L2 SCA28, SPAX5 ENSG00000141385 AFG3-like AAA ATPase 2 18 12328944-12377314 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA004479, HPA004480 Supported Validated Mitochondria Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 121.6 AGBL1 CCP4, FLJ32310 ENSG00000166748 ATP/GTP binding protein-like 1 15 86141996-87029052 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level Not detected Tissue enhanced lung: 1.1;skeletal muscle: 2.1 esophagus: 0.6 AGBL2 CCP2, FLJ23598 ENSG00000165923 ATP/GTP binding protein-like 2 11 47659591-47715389 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007718 Uncertain Mixed Group enriched 7 fallopian tube: 15.2;testis: 22.4 epididymis: 2.8 AGBL3 CCP3, MGC32955 ENSG00000146856 ATP/GTP binding protein-like 3 7 134986508-135147963 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020397, HPA024150 Uncertain Uncertain Nuclear speckles
Mitochondria
Cytosol Renal cancer:4.02e-4 (unfavourable) Mixed Mixed testis: 9.3 AGBL4 CCP6, FLJ14442 ENSG00000186094 ATP/GTP binding protein-like 4 1 48532855-50023913 Enzymes, Predicted intracellular proteins Evidence at transcript level HPA037994 Approved Not detected Tissue enhanced cerebral cortex: 7.9 fallopian tube: 4.6 AGBL5 CCP5, FLJ21839 ENSG00000084693 ATP/GTP binding protein-like 5 2 27042364-27070622 Enzymes, Predicted intracellular proteins Evidence at transcript level HPA030981 Uncertain Approved Cytosol Liver cancer:6.87e-5 (unfavourable) Expressed in all Tissue enriched 6 testis: 357.5 parathyroid gland: 57.3 AGTPBP1 CCP1, KIAA1035, Nna1 ENSG00000135049 ATP/GTP binding protein 1 9 85546539-85742029 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA057208 Approved Approved Nucleoli
Vesicles Expressed in all Expressed in all bone marrow: 39.3 AMZ1 KIAA1950 ENSG00000174945 Archaelysin family metallopeptidase 1 7 2679522-2775500 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020233 Uncertain Mixed Tissue enhanced cerebral cortex: 4.0 endometrium: 1.6 AMZ2 ENSG00000196704 Archaelysin family metallopeptidase 2 17 68247574-68257164 Enzymes, Predicted intracellular proteins Evidence at protein level HPA023299, HPA052406 Approved Supported Nucleoplasm
Nuclear bodies
Cytosol Liver cancer:1.32e-5 (unfavourable), Renal cancer:3.14e-4 (unfavourable) Expressed in all Expressed in all testis: 355.4 ANPEP CD13, gp150, LAP1, p150, PEPN ENSG00000166825 Alanyl (membrane) aminopeptidase 15 89784889-89815401 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002417, HPA004625 Supported Supported Nucleus
Plasma membrane Expressed in all Group enriched 9 duodenum: 2451.4;small intestine: 2177.9 colon: 263.9 ASTL ovastacin, SAS1B ENSG00000188886 Astacin-like metallo-endopeptidase (M12 family) 2 96123850-96138436 Enzymes, Predicted secreted proteins Evidence at protein level HPA015620 Uncertain Mixed Tissue enhanced bone marrow: 2.4 seminal vesicle: 1.4 BMP1 PCOLC ENSG00000168487 Bone morphogenetic protein 1 8 22164736-22212326 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA014572 Approved Renal cancer:3.37e-9 (unfavourable) Expressed in all Tissue enhanced placenta: 21.0 smooth muscle: 10.4 BRCC3 BRCC36, C6.1A, CXorf53 ENSG00000185515 BRCA1/BRCA2-containing complex, subunit 3 X 155071420-155123074 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048737 Supported Nucleoplasm Expressed in all Expressed in all parathyroid gland: 20.8 C9orf3 AOPEP, AP-O, APO, C90RF3, FLJ14675 ENSG00000148120 Chromosome 9 open reading frame 3 9 94726701-95087218 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004633, HPA072729 Approved Approved Cell Junctions Renal cancer:6.33e-5 (favourable) Expressed in all Expressed in all skin: 50.1 CNDP1 CN1, CPGL2, HsT2308, MGC10825 ENSG00000150656 Carnosine dipeptidase 1 (metallopeptidase M20 family) 18 74534440-74587212 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008933 Supported Group enriched Group enriched 12 cerebral cortex: 102.0;liver: 23.0 duodenum: 5.2 CNDP2 CN2, CPGL, FLJ10830, HsT2298, PEPA ENSG00000133313 CNDP dipeptidase 2 (metallopeptidase M20 family) 18 74495816-74523454 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB026196, HPA036898, HPA036899 Supported Validated Nucleoplasm
Cytosol Renal cancer:3.50e-6 (favourable) Expressed in all Expressed in all kidney: 341.1 COPS5 CSN5, JAB1, MOV-34, SGN5 ENSG00000121022 COP9 signalosome subunit 5 8 67043079-67083783 Enzymes, Predicted intracellular proteins Evidence at protein level CAB004242, HPA004845, HPA051531 Supported Validated Nucleoplasm Expressed in all Expressed in all testis: 92.0 COPS6 CSN6, MOV34-34KD ENSG00000168090 COP9 signalosome subunit 6 7 100088954-100092200 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044315 Approved Supported Nucleoplasm Renal cancer:6.72e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 127.1 CPA1 CPA ENSG00000091704 Carboxypeptidase A1 (pancreatic) 7 130380339-130388114 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021836, CAB025197, HPA052215 Supported Tissue enriched Tissue enriched 366 pancreas: 48833.8 ovary: 133.3 CPA2 ENSG00000158516 Carboxypeptidase A2 (pancreatic) 7 130266827-130289798 Enzymes, Predicted secreted proteins Evidence at protein level HPA020342, HPA021317 Supported Tissue enriched Tissue enriched 107 pancreas: 9279.4 stomach: 86.6 CPA3 ENSG00000163751 Carboxypeptidase A3 (mast cell) 3 148865256-148897196 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA006479, HPA008689, CAB020712 Supported Mixed Tissue enhanced gallbladder: 174.4 lung: 126.7 CPA4 CPA3 ENSG00000128510 Carboxypeptidase A4 7 130293134-130324180 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021030 Uncertain Approved Nucleoplasm
Centrosome
Cytosol Urothelial cancer:1.31e-4 (unfavourable) Tissue enhanced Tissue enriched 7 skin: 68.0 esophagus: 10.0 CPA5 ENSG00000158525 Carboxypeptidase A5 7 130344816-130368730 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020322 Approved Nucleus Not detected Tissue enriched 11 testis: 47.1 spleen: 4.2 CPA6 CPAH ENSG00000165078 Carboxypeptidase A6 8 67422125-67746345 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level Mixed Tissue enhanced prostate: 6.9;rectum: 3.8 colon: 2.4 CPB1 ENSG00000153002 Carboxypeptidase B1 (tissue) 3 148791102-148860187 Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026158, HPA038069, HPA046340 Supported Group enriched Tissue enriched 311 pancreas: 47265.6 ovary: 151.9 CPB2 CPU, PCPB, TAFI ENSG00000080618 Carboxypeptidase B2 (plasma) 13 46053186-46105076 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004146 Approved Liver cancer:2.06e-4 (favourable) Tissue enriched Tissue enriched 28 liver: 754.0 lung: 26.5 CPD GP180 ENSG00000108582 Carboxypeptidase D 17 30378905-30469989 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052796, HPA055465 Approved Approved Nucleoplasm
Nuclear membrane
Nuclear speckles Expressed in all Expressed in all thyroid gland: 94.6 CPE ENSG00000109472 Carboxypeptidase E 4 165361194-165498320 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003819, CAB024907 Supported Approved Nucleoplasm
Vesicles
Centrosome Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 1564.8 CPM ENSG00000135678 Carboxypeptidase M 12 68842197-68971570 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002657, HPA077243 Uncertain Uncertain Vesicles Endometrial cancer:1.00e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 163.6 placenta: 100.2 CPN1 ENSG00000120054 Carboxypeptidase N, polypeptide 1 10 100042193-100081877 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040323 Approved Nucleus
Nucleoli Group enriched Tissue enriched 22 liver: 37.0 testis: 1.7 CPO ENSG00000144410 Carboxypeptidase O 2 206939554-206969474 Enzymes, Predicted secreted proteins Evidence at transcript level Not detected Tissue enriched 15 small intestine: 133.7 epididymis: 9.2 CPQ LDP, PGCP ENSG00000104324 Carboxypeptidase Q 8 96645227-97149654 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA023235, HPA024490 Supported Approved Golgi apparatus
Vesicles Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 380.7 CPXM1 CPX-1, CPX1, CPXM ENSG00000088882 Carboxypeptidase X (M14 family), member 1 20 2794069-2800637 Enzymes, Predicted secreted proteins Evidence at protein level Renal cancer:4.62e-10 (unfavourable) Expressed in all Tissue enhanced endometrium: 130.2;gallbladder: 132.9 urinary bladder: 77.4 CPXM2 CPX2, UNQ676 ENSG00000121898 Carboxypeptidase X (M14 family), member 2 10 123706207-123940267 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA048375 Uncertain Renal cancer:9.02e-4 (favourable) Expressed in all Tissue enhanced epididymis: 71.4;smooth muscle: 79.7 urinary bladder: 35.5 CPZ ENSG00000109625 Carboxypeptidase Z 4 8592660-8619759 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Mixed Tissue enhanced ovary: 121.2 placenta: 57.7 DNPEP ASPEP, DAP ENSG00000123992 Aspartyl aminopeptidase 2 219373546-219400022 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036398, HPA044860 Supported Supported Cytosol Expressed in all Expressed in all testis: 65.8 DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Supported Approved Nucleus
Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.3;small intestine: 426.5 pancreas: 92.8 DPEP2 ENSG00000167261 Dipeptidase 2 16 67987394-68000586 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035644 Approved Testis cancer:8.47e-4 (unfavourable) Mixed Tissue enhanced spleen: 39.4 lung: 28.2 DPEP3 ENSG00000141096 Dipeptidase 3 16 67975663-67980829 Enzymes, Predicted secreted proteins Evidence at protein level HPA031870, HPA058607 Supported Group enriched Tissue enriched 24 testis: 56.8 spleen: 2.3 DPP3 ENSG00000254986 Dipeptidyl-peptidase 3 11 66480013-66509657 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035780, HPA035781 Approved Validated Nuclear speckles
Plasma membrane
Cytosol Stomach cancer:1.34e-4 (favourable) Expressed in all Expressed in all colon: 30.0 ECE1 ECE ENSG00000117298 Endothelin converting enzyme 1 1 21217247-21345504 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001490, HPA013616 Approved Expressed in all Expressed in all parathyroid gland: 428.4 ECE2 KIAA0604, MGC2408 ENSG00000145194 Endothelin converting enzyme 2 3 184249650-184293031 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043346, HPA062215 Approved Approved Nucleus
Cytosol Endometrial cancer:8.41e-5 (unfavourable), Liver cancer:5.80e-4 (unfavourable) Expressed in all Mixed adrenal gland: 15.5 ECEL1 DINE, XCE ENSG00000171551 Endothelin converting enzyme-like 1 2 232479827-232487828 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067560 Approved Nucleoplasm
Nuclear membrane
Nucleoli Tissue enhanced Tissue enriched 24 ovary: 111.9 spleen: 4.6 ENPEP CD249, gp160 ENSG00000138792 Glutamyl aminopeptidase (aminopeptidase A) 4 110365733-110565285 CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005128 Approved Tissue enriched Group enriched 5 duodenum: 37.5;kidney: 93.6;parathyroid gland: 157.9;small intestine: 183.8 placenta: 21.5 ERAP1 A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP ENSG00000164307 Endoplasmic reticulum aminopeptidase 1 5 96760810-96808100 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025095, HPA042317 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Expressed in all placenta: 68.5 ERAP2 L-RAP, LRAP ENSG00000164308 Endoplasmic reticulum aminopeptidase 2 5 96875939-96919716 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025618, HPA034498 Supported Uncertain Mitochondria Pancreatic cancer:1.20e-4 (unfavourable) Expressed in all Mixed lymph node: 50.0 ERMP1 FLJ23309, FXNA, KIAA1815 ENSG00000099219 Endoplasmic reticulum metallopeptidase 1 9 5765076-5833117 Enzymes, Predicted membrane proteins Evidence at protein level HPA020584 Approved Approved Nucleus
Nucleoli Renal cancer:5.83e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 122.3 thyroid gland: 43.8 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 IDE ENSG00000119912 Insulin-degrading enzyme 10 92451684-92574076 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063478 Approved Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable) Expressed in all Expressed in all skin: 63.5 KEL CD238, ECE3 ENSG00000197993 Kell blood group, metallo-endopeptidase 7 142941114-142962681 Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 14.6;testis: 19.4 lymph node: 6.5 LAP3 LAP, LAPEP, PEPS ENSG00000002549 Leucine aminopeptidase 3 4 17577192-17607972 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029606, HPA029607 Supported Supported Nucleoplasm
Midbody
Cytosol Expressed in all Expressed in all appendix: 182.0 LMLN Gp63, Msp ENSG00000185621 Leishmanolysin-like (metallopeptidase M8 family) 3 197960200-198043720 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016481, HPA028844 Uncertain Supported Focal adhesion sites
Cytosol Endometrial cancer:6.77e-4 (favourable) Expressed in all Tissue enhanced testis: 18.7 epididymis: 12.7 LNPEP CAP, P-LAP, PLAP ENSG00000113441 Leucyl/cystinyl aminopeptidase 5 96935394-97037515 Enzymes, Predicted membrane proteins Evidence at protein level HPA043642 Approved Expressed in all Mixed parathyroid gland: 22.9 LTA4H ENSG00000111144 Leukotriene A4 hydrolase 12 96000828-96043520 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008399, CAB015221, HPA017017 Supported Supported Nucleoplasm
Cytosol Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable) Expressed in all Expressed in all lung: 283.6 LVRN APQ, AQPEP, FLJ90650, TAQPEP ENSG00000172901 Laeverin 5 115962454-116027619 Enzymes, Predicted secreted proteins Evidence at protein level HPA053254 Approved Not detected Group enriched 22 adipose tissue: 11.8;placenta: 31.2 breast: 0.9 MBTPS2 KFSD, S2P ENSG00000012174 Membrane-bound transcription factor peptidase, site 2 X 21839636-21885424 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA005494, CAB009486 Approved Approved Nucleoplasm
Mitochondria
Cytosol Expressed in all Expressed in all parathyroid gland: 19.0 MEP1A PPHA ENSG00000112818 Meprin A, alpha (PABA peptide hydrolase) 6 46793390-46839782 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025163, HPA029416 Supported Tissue enriched Group enriched 41 colon: 120.0;duodenum: 290.0;rectum: 116.2;small intestine: 549.0 appendix: 6.5 MEP1B ENSG00000141434 Meprin A, beta 18 32185069-32220404 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029119 Supported Group enriched Group enriched 34 duodenum: 258.3;small intestine: 410.0 colon: 9.9 METAP1 KIAA0094, MAP1A, MetAP1A ENSG00000164024 Methionyl aminopeptidase 1 4 98995620-99062813 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025485, HPA037997, HPA037998 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable) Expressed in all Expressed in all testis: 76.9 METAP1D MAP1D, Metap1l ENSG00000172878 Methionyl aminopeptidase type 1D (mitochondrial) 2 171999583-172082430 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030298, HPA030299 Uncertain Supported Vesicles Expressed in all Mixed ovary: 9.2 METAP2 MAP2, MNPEP, p67 ENSG00000111142 Methionyl aminopeptidase 2 12 95473520-95515839 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013025, HPA019095 Supported Supported Plasma membrane
Cytosol Liver cancer:4.51e-6 (unfavourable) Expressed in all Expressed in all seminal vesicle: 141.9 MIPEP MIP ENSG00000027001 Mitochondrial intermediate peptidase 13 23730189-23889419 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030676, HPA031669, HPA031670 Approved Validated Mitochondria Renal cancer:7.66e-12 (favourable) Expressed in all Expressed in all fallopian tube: 27.1 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MMEL1 MMEL2, NEPII, NL1, NL2, SEP ENSG00000142606 Membrane metallo-endopeptidase-like 1 1 2590639-2632990 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007876, HPA008205, CAB020786 Uncertain Mixed Tissue enhanced testis: 5.4 stomach: 2.3 MMP1 CLG ENSG00000196611 Matrix metallopeptidase 1 11 102789920-102798160 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004920 Supported Vesicles Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 39.7;gallbladder: 126.6 urinary bladder: 30.2 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 MMP11 STMY3 ENSG00000099953 Matrix metallopeptidase 11 22 23768226-23784316 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002593, HPA068864 Approved Renal cancer:2.62e-4 (unfavourable) Expressed in all Group enriched 9 cervix, uterine: 30.9;endometrium: 122.3;placenta: 27.9 smooth muscle: 6.4 MMP12 HME ENSG00000262406 Matrix metallopeptidase 12 11 102862736-102875034 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Liver cancer:1.42e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 55.9;urinary bladder: 29.8 tonsil: 17.9 MMP13 CLG3 ENSG00000137745 Matrix metallopeptidase 13 11 102942995-102955734 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced lung: 1.5;urinary bladder: 1.4 appendix,testis: 0.3 MMP14 MT1-MMP ENSG00000157227 Matrix metallopeptidase 14 (membrane-inserted) 14 22836557-22849027 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009918, HPA051432 Approved Approved Intermediate filaments
Cytosol Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable) Expressed in all Mixed endometrium: 236.1 MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 (membrane-inserted) 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 69.9 duodenum: 39.8 MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 (membrane-inserted) 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 MMP17 MT4-MMP ENSG00000198598 Matrix metallopeptidase 17 (membrane-inserted) 12 131828393-131851783 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced cerebral cortex: 24.1 skin: 8.2 MMP19 MMP18, RASI-1 ENSG00000123342 Matrix metallopeptidase 19 12 55835433-55842966 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA070804 Approved Endoplasmic reticulum
Vesicles Renal cancer:8.56e-9 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 63.1;gallbladder: 97.5 placenta: 27.9 MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles
Cytosol Expressed in all Tissue enhanced gallbladder: 1688.5 urinary bladder: 944.6 MMP20 ENSG00000137674 Matrix metallopeptidase 20 11 102576835-102625332 Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Group enriched 5 breast: 1.2;testis: 1.1 tonsil: 0.2 MMP21 ENSG00000154485 Matrix metallopeptidase 21 10 125766453-125775821 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 27 epididymis: 58.2 ovary: 2.1 MMP23B MIFR, MIFR-1, MMP22 ENSG00000189409 Matrix metallopeptidase 23B 1 1632095-1701810 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level Tissue enhanced Mixed placenta: 4.4 MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 (membrane-inserted) 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli
Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.1 MMP25 MMP20, MMPL1, MT6-MMP ENSG00000008516 Matrix metallopeptidase 25 16 3046681-3060726 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025177 Uncertain Head and neck cancer:1.09e-5 (favourable) Tissue enhanced Tissue enhanced appendix: 23.9;bone marrow: 24.7;spleen: 21.1 adipose tissue: 6.3 MMP26 endometase, MGC126590, MGC126592 ENSG00000167346 Matrix metallopeptidase 26 11 4704927-4992429 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at transcript level Group enriched Tissue enriched 64 endometrium: 23.8 prostate,testis: 0.3 MMP27 ENSG00000137675 Matrix metallopeptidase 27 11 102691487-102705806 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA069097 Approved Not detected Group enriched 5 breast: 6.0;skin: 2.8 bone marrow: 0.8 MMP28 EPILYSIN, MM28, MMP-25, MMP-28 ENSG00000271447 Matrix metallopeptidase 28 17 35756249-35795707 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:6.28e-6 (unfavourable) Mixed Tissue enhanced testis: 6.4 adipose tissue: 4.2 MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Approved Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.9;endometrium: 58.7 urinary bladder: 9.2 MMP7 MPSL1, PUMP-1 ENSG00000137673 Matrix metallopeptidase 7 11 102520508-102530753 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025869, HPA051358 Supported Approved Nucleoplasm
Vesicles Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 824.4 breast: 201.5 MMP8 CLG1 ENSG00000118113 Matrix metallopeptidase 8 11 102711795-102727050 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021221, HPA022935 Supported Tissue enriched Tissue enriched 103 bone marrow: 336.3 endometrium: 3.2 MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Supported Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 253.0;lymph node: 119.4 appendix: 85.4 MPND FLJ14981 ENSG00000008382 MPN domain containing 19 4343527-4360086 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043274, HPA045475 Approved Approved Nucleus
Nucleoli Lung cancer:1.55e-4 (favourable), Cervical cancer:2.99e-4 (favourable), Endometrial cancer:6.12e-4 (favourable), Renal cancer:7.04e-4 (favourable) Expressed in all Expressed in all duodenum: 31.8 MYSM1 KIAA1915 ENSG00000162601 Myb-like, SWIRM and MPN domains 1 1 58654739-58700092 Enzymes, Predicted intracellular proteins Evidence at protein level HPA054291, HPA067133 Approved Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.09e-5 (favourable) Expressed in all Mixed skin: 11.1 NAALAD2 GPCIII, NAADALASE2, NAALADASE2 ENSG00000077616 N-acetylated alpha-linked acidic dipeptidase 2 11 90131515-90192894 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060820, HPA065419 Approved Approved Nucleus Tissue enhanced Tissue enhanced testis: 27.2 adrenal gland,endometrium: 13.7 NAALADL1 ENSG00000168060 N-acetylated alpha-linked acidic dipeptidase-like 1 11 65044818-65058549 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047123 Approved Uncertain Cytosol Expressed in all Tissue enriched 5 small intestine: 106.2 duodenum: 20.7 NAALADL2 ENSG00000177694 N-acetylated alpha-linked acidic dipeptidase-like 2 3 174438573-175810552 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012413, HPA017425, CAB025586 Approved Mixed Tissue enhanced parathyroid gland: 42.8 cervix, uterine: 11.8 NLN AGTBP, KIAA1226 ENSG00000123213 Neurolysin (metallopeptidase M3 family) 5 65722196-65871725 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031862 Approved Approved Mitochondria Renal cancer:5.58e-7 (favourable), Pancreatic cancer:7.51e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 8.3 NPEPL1 bA261P9.2, FLJ11583 ENSG00000215440 Aminopeptidase-like 1 20 58689131-58719238 Enzymes, Predicted intracellular proteins Evidence at protein level CAB004986, CAB017025, HPA036356 Approved Approved Nucleoplasm Renal cancer:1.87e-9 (unfavourable), Urothelial cancer:5.73e-4 (favourable) Expressed in all Expressed in all spleen: 25.2 NPEPPS MP100, PSA ENSG00000141279 Aminopeptidase puromycin sensitive 17 47522942-47623276 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021453, HPA045649 Uncertain Supported Cytosol Colorectal cancer:3.39e-5 (favourable), Liver cancer:3.67e-5 (unfavourable) Expressed in all Expressed in all esophagus: 107.3 NRD1 hNRD1, hNRD2 ENSG00000078618 Nardilysin (N-arginine dibasic convertase) 1 51789191-51878937 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA053661 Approved Nucleoplasm Renal cancer:2.12e-9 (unfavourable), Liver cancer:5.49e-6 (unfavourable) Expressed in all Expressed in all testis: 167.1 OMA1 FLJ33782, MPRP-1, YKR087C, ZMPOMA1 ENSG00000162600 OMA1 zinc metallopeptidase 1 58415384-58546802 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055120 Approved Approved Nucleoplasm
Mitochondria Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable) Expressed in all Expressed in all prostate: 32.2 PA2G4 ENSG00000170515 Proliferation-associated 2G4, 38kDa 12 56104319-56113907 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011711, CAB012428, HPA016484 Supported Approved Cytosol Renal cancer:4.59e-7 (unfavourable), Liver cancer:6.31e-7 (unfavourable) Expressed in all Expressed in all parathyroid gland: 136.0 PAPPA ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1 ENSG00000182752 Pregnancy-associated plasma protein A, pappalysin 1 9 116153804-116402322 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001667, CAB016724 Supported Uncertain Plasma membrane
Cytosol Mixed Tissue enriched 7 placenta: 103.9 parathyroid gland: 14.6 PAPPA2 PAPP-A2, PAPPE, PLAC3 ENSG00000116183 Pappalysin 2 1 176463171-176845605 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018412, HPA018430 Supported Approved Endoplasmic reticulum
Vesicles Mixed Tissue enriched 8 placenta: 82.1 cervix, uterine: 10.8 PEPD ENSG00000124299 Peptidase D 19 33386950-33521794 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015599 Approved Approved Nucleoplasm Renal cancer:6.50e-9 (favourable) Expressed in all Expressed in all kidney: 341.0 PHEX HPDR, HPDR1, HYP, HYP1, PEX, XLH ENSG00000102174 Phosphate regulating endopeptidase homolog, X-linked X 22032441-22251310 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level Thyroid cancer:2.51e-4 (favourable) Tissue enhanced Mixed endometrium: 3.5 PITRM1 hMP1, KIAA1104, MP1, PreP ENSG00000107959 Pitrilysin metallopeptidase 1 10 3137728-3172841 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006753, HPA006754 Supported Supported Mitochondria Expressed in all Expressed in all testis: 87.9 PM20D1 Cps1, FLJ32569 ENSG00000162877 Peptidase M20 domain containing 1 1 205828022-205850132 Enzymes, Predicted secreted proteins Evidence at transcript level Tissue enriched Tissue enhanced kidney: 5.9;pancreas: 16.6 skin: 3.9 PM20D2 ACY1L2, bA63L7.3 ENSG00000146281 Peptidase M20 domain containing 2 6 89146050-89165565 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030325, HPA030326, HPA030327 Approved Validated Nucleoplasm Expressed in all Expressed in all prostate: 39.3 PMPCA Alpha-MPP, INPP5E, KIAA0123 ENSG00000165688 Peptidase (mitochondrial processing) alpha 9 136410570-136423761 Enzymes, Predicted intracellular proteins Evidence at protein level HPA021648, HPA063735 Supported Validated Mitochondria Renal cancer:2.14e-6 (favourable), Pancreatic cancer:8.00e-5 (favourable) Expressed in all Expressed in all adrenal gland: 38.8 PMPCB MPPB, MPPP52 ENSG00000105819 Peptidase (mitochondrial processing) beta 7 103297422-103329511 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040674, HPA074168 Approved Supported Mitochondria Renal cancer:2.95e-8 (favourable), Breast cancer:2.79e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 68.9 PSMD14 pad1, POH1, Rpn11 ENSG00000115233 Proteasome 26S subunit, non-ATPase 14 2 161308038-161411717 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002114, HPA003828 Approved Supported Nucleoplasm Liver cancer:2.66e-8 (unfavourable), Renal cancer:3.10e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 56.3 PSMD7 MOV34, P40, Rpn8, S12 ENSG00000103035 Proteasome 26S subunit, non-ATPase 7 16 74296775-74306288 Enzymes, Predicted intracellular proteins Evidence at protein level CAB019379, HPA049824, HPA056069 Approved Validated Nucleoplasm Liver cancer:7.71e-6 (unfavourable), Head and neck cancer:6.64e-5 (unfavourable) Expressed in all Expressed in all prostate: 109.5 RNPEP ENSG00000176393 Arginyl aminopeptidase (aminopeptidase B) 1 201982372-202006147 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036074, HPA036075, HPA061487 Approved Supported Nucleoplasm
Golgi apparatus Expressed in all Expressed in all duodenum: 68.3 RNPEPL1 ENSG00000142327 Arginyl aminopeptidase (aminopeptidase B)-like 1 2 240565804-240581372 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036772 Uncertain Approved Nucleus
Nucleoli Liver cancer:5.06e-4 (unfavourable), Head and neck cancer:7.43e-4 (favourable) Expressed in all Expressed in all skin: 29.4 SPG7 CAR, CMAR, SPG5C ENSG00000197912 Spastic paraplegia 7 (pure and complicated autosomal recessive) 16 89490917-89557768 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable) Expressed in all Expressed in all thyroid gland: 52.3 STAMBP AMSH ENSG00000124356 STAM binding protein 2 73828916-73873659 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA035800 Uncertain Supported Nucleoplasm
Plasma membrane
Cytosol Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.2 STAMBPL1 ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373 ENSG00000138134 STAM binding protein-like 1 10 88879734-88975153 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040202 Uncertain Approved Plasma membrane Renal cancer:1.08e-5 (unfavourable) Mixed Mixed adrenal gland,testis: 29.8 SUPT16H CDC68, FACT, FACTP140, FLJ10857, FLJ14010, SPT16/CDC68 ENSG00000092201 SPT16 homolog, facilitates chromatin remodeling subunit 14 21351472-21384266 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022551, HPA049787 Supported Supported Nucleus
Nucleoli fibrillar center Expressed in all Expressed in all parathyroid gland: 94.3 TCAF1 FAM115A, KIAA0738 ENSG00000198420 TRPM8 channel-associated factor 1 7 143851375-143902198 Enzymes, Predicted intracellular proteins Evidence at protein level HPA011732, HPA061989 Approved Supported Nucleoplasm
Mitochondria Ovarian cancer:5.93e-4 (favourable) Expressed in all Expressed in all placenta: 115.3 TCAF2 FAM115C, FAM139A, FLJ40722 ENSG00000170379 TRPM8 channel-associated factor 2 7 143620950-143730409 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038756, HPA038758 Uncertain Supported Endoplasmic reticulum
Plasma membrane
Cell Junctions Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable) Mixed Mixed placenta: 8.4 TFR2 HFE3, TFRC2 ENSG00000106327 Transferrin receptor 2 7 100620416-100642779 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA011937, CAB016255 Supported Liver cancer:2.48e-4 (favourable) Tissue enriched Tissue enriched 11 liver: 155.8 bone marrow: 13.9 TFRC CD71, p90, TFR1 ENSG00000072274 Transferrin receptor 3 196027183-196082189 Cancer-related genes, CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000153, HPA028598 Supported Supported Endosomes
Lysosomes Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 157.6 THOP1 ENSG00000172009 Thimet oligopeptidase 1 19 2785460-2815807 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025497, HPA035262 Uncertain Supported Cytosol Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable) Expressed in all Expressed in all testis: 36.2 TLL1 ENSG00000038295 Tolloid-like 1 4 165873258-166103895 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA060767 Approved Vesicles Mixed Tissue enhanced placenta: 10.4 gallbladder: 4.4 TLL2 ENSG00000095587 Tolloid-like 2 10 96364606-96513918 Enzymes, Predicted secreted proteins Evidence at protein level Mixed Tissue enhanced cerebral cortex: 1.9 heart muscle: 0.9 TRHDE PAP-II, PGPEP2, TRH-DE ENSG00000072657 Thyrotropin-releasing hormone degrading enzyme 12 72087266-72670757 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:1.53e-7 (favourable) Tissue enhanced Mixed cerebral cortex: 8.0 UQCRC1 D3S3191, QCR1, UQCR1 ENSG00000010256 Ubiquinol-cytochrome c reductase core protein I 3 48599002-48610976 Enzymes, Predicted intracellular proteins Evidence at protein level HPA002815, HPA003525, CAB033782 Supported Supported Mitochondria
Cytosol Renal cancer:2.35e-10 (favourable) Expressed in all Expressed in all skeletal muscle: 88.3 UQCRC2 QCR2, UQCR2 ENSG00000140740 Ubiquinol-cytochrome c reductase core protein II 16 21952660-21983660 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007998, HPA019146 Supported Validated Mitochondria Renal cancer:6.58e-9 (favourable) Expressed in all Expressed in all heart muscle: 296.6 XPNPEP1 XPNPEP, XPNPEPL, XPNPEPL1 ENSG00000108039 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 10 109864766-109923553 Enzymes, Predicted intracellular proteins Evidence at protein level CAB025196, HPA030419, HPA030420, HPA030422 Supported Validated Cytosol Liver cancer:2.12e-5 (unfavourable) Expressed in all Expressed in all small intestine: 67.5 XPNPEP2 ENSG00000122121 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound X 129738974-129769538 Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA000339, CAB025136, CAB025269 Supported Approved Golgi apparatus Group enriched Group enriched 13 duodenum: 131.6;kidney: 174.6;small intestine: 236.2 liver: 14.3 XPNPEP3 APP3, ICP55, NPHPL1 ENSG00000196236 X-prolyl aminopeptidase 3, mitochondrial 22 40857077-40932815 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000527 Approved Thyroid cancer:6.10e-4 (unfavourable), Breast cancer:8.19e-4 (unfavourable) Expressed in all Mixed duodenum: 14.9 XRCC6BP1 KUB3 ENSG00000166896 XRCC6 binding protein 1 12 57941541-57957269 Enzymes, Predicted intracellular proteins Evidence at protein level HPA035804, HPA043204 Uncertain Validated Vesicles
Plasma membrane
Cell Junctions
Cytosol Renal cancer:1.44e-5 (unfavourable) Expressed in all Tissue enhanced testis: 26.6 rectum: 5.6 YME1L1 ENSG00000136758 YME1-like 1 ATPase 10 27110112-27155266 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066953 Approved Supported Nuclear bodies
Mitochondria Liver cancer:8.25e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 105.3 ZMPSTE24 FACE-1, HGPS, PRO1, STE24, Ste24p ENSG00000084073 Zinc metallopeptidase STE24 1 40258107-40294184 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006988 Approved Approved Golgi apparatus
Cytosol Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 89.0